Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.32 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100703 | 0.93 | JAK2 (0.38) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100392 | 0.91 | JAK2 (0.38) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100574 | 0.90 | JAK2 (0.37) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100487 | 0.90 | JAK2 (0.37) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100534 | 0.90 | JAK2 (0.37) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100434 | 0.89 | JAK2 (0.36) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100653 | 0.89 | JAK2 (0.37) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100650 | 0.89 | JAK2 (0.37) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100671 | 0.88 | JAK2 (0.38) | JAK2MAPK1LRRK2PRMT5WDR77 | |
| SCHEMBL10100403 | 0.88 | JAK2 (0.36) | JAK2MAPK1LRRK2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2350045-A1 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | JAK2 59/4885MAPK1 357/4885LRRK2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.